Researchers identify anticoagulation agent that suppresses S
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction.

In an analysis of a randomly collected cohort of 124 patients with COVID-19, the authors found that hypercoagulability, as indicated by elevated concentrations of D-dimers, was associated with disease severity.

By virtual screening of a U.S. FDA approved drug library, the authors identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication invitro.

In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P<0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes for the severely ill patients in comparison to the control patients.

In summary, DIP could be used for the treatment of severely ill patients with COVID-19 through antiviral and anticoagulation effects.

Source: https://www.sciencedirect.com/science/article/pii/S2211383520305529?via=ihub
P●●●●i P●●●●●n and 26 others like this20 shares
Like
Comment
Share